Zegbeh Jallah
Stock Analyst at Capital One
(3.82)
# 2,039
Out of 4,479 analysts
24
Total ratings
38.89%
Success rate
145.7%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgrades: Overweight | $100 | $7.09 | +1,310.44% | 2 | Dec 27, 2023 | |
| GLYC GlycoMimetics | Initiates: Overweight | $12 | $0.27 | +4,364.29% | 1 | Dec 22, 2023 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $44 | $8.01 | +449.31% | 1 | Dec 11, 2023 | |
| KOD Kodiak Sciences | Upgrades: Overweight | n/a | $2.24 | - | 4 | Nov 17, 2023 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $29 | $33.72 | -14.00% | 2 | Dec 28, 2022 | |
| RAPT RAPT Therapeutics | Initiates: Overweight | $48 | $2.79 | +1,620.43% | 2 | Sep 21, 2022 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $101 → $70 | $13.45 | +420.45% | 2 | May 12, 2022 | |
| SYRS Syros Pharmaceuticals | Maintains: Buy | n/a | $5.00 | - | 1 | Sep 23, 2021 | |
| RZLT Rezolute | Initiates: Buy | n/a | $4.21 | - | 1 | Sep 8, 2021 | |
| ARVN Arvinas | Maintains: Buy | n/a | $24.85 | - | 1 | Aug 9, 2021 | |
| DARE Daré Bioscience | Maintains: Buy | n/a | $3.63 | - | 1 | Jun 30, 2021 | |
| OCGN Ocugen | Downgrades: Neutral | n/a | $1.61 | - | 2 | Jun 11, 2021 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | n/a | $11.51 | - | 1 | Feb 18, 2021 | |
| IVA Inventiva | Initiates: Buy | n/a | $2.85 | - | 1 | Aug 5, 2020 | |
| CLSD Clearside Biomedical | Initiates: Buy | n/a | $1.23 | - | 1 | May 13, 2020 | |
| XFOR X4 Pharmaceuticals | Initiates: Buy | n/a | $0.54 | - | 1 | Dec 18, 2019 |
Outlook Therapeutics
Dec 27, 2023
Upgrades: Overweight
Price Target: $100
Current: $7.09
Upside: +1,310.44%
GlycoMimetics
Dec 22, 2023
Initiates: Overweight
Price Target: $12
Current: $0.27
Upside: +4,364.29%
EyePoint Pharmaceuticals
Dec 11, 2023
Initiates: Overweight
Price Target: $44
Current: $8.01
Upside: +449.31%
Kodiak Sciences
Nov 17, 2023
Upgrades: Overweight
Price Target: n/a
Current: $2.24
Upside: -
IDEAYA Biosciences
Dec 28, 2022
Initiates: Overweight
Price Target: $29
Current: $33.72
Upside: -14.00%
RAPT Therapeutics
Sep 21, 2022
Initiates: Overweight
Price Target: $48
Current: $2.79
Upside: +1,620.43%
Enanta Pharmaceuticals
May 12, 2022
Maintains: Buy
Price Target: $101 → $70
Current: $13.45
Upside: +420.45%
Syros Pharmaceuticals
Sep 23, 2021
Maintains: Buy
Price Target: n/a
Current: $5.00
Upside: -
Rezolute
Sep 8, 2021
Initiates: Buy
Price Target: n/a
Current: $4.21
Upside: -
Arvinas
Aug 9, 2021
Maintains: Buy
Price Target: n/a
Current: $24.85
Upside: -
Daré Bioscience
Jun 30, 2021
Maintains: Buy
Price Target: n/a
Current: $3.63
Upside: -
Ocugen
Jun 11, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
KalVista Pharmaceuticals
Feb 18, 2021
Maintains: Buy
Price Target: n/a
Current: $11.51
Upside: -
Inventiva
Aug 5, 2020
Initiates: Buy
Price Target: n/a
Current: $2.85
Upside: -
Clearside Biomedical
May 13, 2020
Initiates: Buy
Price Target: n/a
Current: $1.23
Upside: -
X4 Pharmaceuticals
Dec 18, 2019
Initiates: Buy
Price Target: n/a
Current: $0.54
Upside: -